<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002209</url>
  </required_header>
  <id_info>
    <org_study_id>289A</org_study_id>
    <secondary_id>CPI001189-MAD01</secondary_id>
    <nct_id>NCT00002209</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy</brief_title>
  <official_title>Multiple Ascending Dose Pharmacokinetics of CPI-1189 (LU 02-584) in Fasted, HIV Infected, Male Volunteers on Combined Reverse Transcriptase and Protease Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centaur Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe to give multiple doses of CPI-1189 to&#xD;
      HIV-infected, otherwise healthy, males. The study will also look at how CPI-1189 affects the&#xD;
      levels of HIV, T cells (cells in the body that help fight infection), and three anti-HIV&#xD;
      drugs (zidovudine, lamivudine, and indinavir) in the blood.&#xD;
&#xD;
      Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to losses of&#xD;
      memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Late-stage HIV infection can cause AIDS dementia (brain damage due to HIV leading to losses&#xD;
      of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it&#xD;
      down.&#xD;
&#xD;
      In this randomized, double-blind study, 48 HIV-infected, otherwise healthy, male volunteers&#xD;
      receive either multiple-dose CPI-1189 or placebo by mouth for 15 consecutive days. Each&#xD;
      dosing group begins 6 weeks following the start of the preceding group. Volunteers enter the&#xD;
      study site the night before dosing on Days 1 and 15 and remain at the study site for 72 hours&#xD;
      following dosing. Throughout the study, volunteers have physical exams and donate samples of&#xD;
      blood, urine, cerebrospinal fluid, and sperm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>48</enrollment>
  <condition>AIDS Dementia Complex</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-1189</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        You may be eligible for this study if you:&#xD;
&#xD;
          -  Are an HIV-positive man who is otherwise in good health.&#xD;
&#xD;
          -  Are 18-50 years old.&#xD;
&#xD;
          -  Have a CD4 count of 75-500 cells/mm3.&#xD;
&#xD;
          -  Are currently taking zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MDS Harris</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>AIDS Dementia Complex</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Indinavir</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>AIDS Dementia Complex</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

